Video
Dr. Mato Discusses the Safety and Efficacy of Umbralisib in CLL
Author(s):
Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia.
Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL).
This phase II study evaluated the safety and efficacy of the next-generation PI3K inhibitor umbralisib in patients with CLL who are intolerant to prior therapy with either a Bruton’s kinase inhibitor, or a PI3K inhibitor. In results presented during the 2018 European Hematology Association Congress, umbralisib showed to be safe in effective in this population.
The toxicity profile was quite impressive Mato says, with relatively few grade 3/4 events. The primary endpoint was progression-free survival (PFS) with a median follow-up of 9.5 months. The median PFS has not yet been reached. There has only been 1 death on the study, and 6 patients had to discontinue treatment due to adverse events.
